The Brenden-Colson Center for Pancreatic Care has joined the Pancreatic Cancer Early Detection (PRECEDE) Consortium. The PRECEDE Consortium is an international, multi-institutional collaborative group of experts working to improve survival for patients with pancreatic cancer. Through this novel collaboration and data sharing platform, researchers are making strides in early detection, surveillance, risk modeling and prevention for those at risk for pancreatic cancer.
PRECEDE's goal is to increase the pancreatic cancer 5-year survival rate to 50% in the next 10 years!
As part of the PRECEDE study, clinical information, family history and samples (such as blood, saliva or cheek swab) are collected from people and families at risk for pancreatic cancer. These data create a resource necessary to drive pancreatic cancer early detection and prevention research.
Meet the OHSU PRECEDE Team
Want to join the PRECEDE Consortium?
The PRECEDE Consortium is the largest high-risk patient cohort!
Do you or a family member have a history of pancreatic cancer? Then you may be eligible to participate in the PRECEDE study. Our team would be happy to meet with you.
Study participation may include:
- Providing a blood sample at each clinic visit (1-2 times/year) and at any clinical follow up if abnormal findings are seen with imaging or lab studies
- Providing medical and family history information
- Permission to access your medical records and retrieve results from routine clinical care (e.g., genetic testing, imaging studies)
- If you are diagnosed with pancreatic cancer, you will be asked to donate extra tissue at the time of clinical biopsies or surgeries
If you believe you are eligible to participate in the PRECEDE Consortium, you may also want to talk to your primary care provider to see about a referral to OHSU’s Pancreatic High Risk Clinic.